TX-TANGO-NETWORKS
Tango Networks today announced Global Pass, a single rate subscription plan for Tango Extend across 39 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312069630/en/
Tango Extend Global Pass sets the new benchmark for global business mobile communications under a single subscription plan. (Photo: Business Wire)
The Tango Extend eSIM service already enables any subscriber’s smartphone to integrate directly with a company’s Unified Communications (UC) platform to provide remote employees, frontline, deskless and hybrid workers with seamless business communications.
Now, with Global Pass, Tango Extend subscribers enjoy a single fixed-rate business mobile service across 14 Home countries with seamless roaming in a further 25 Home Away countries across Europe and North America.
“Global Pass is a game-changer, enhancing the capabilities of Tango Extend to redefine how enterprises connect, communicate, and collaborate on a global basis,” said Lee Essex, Senior Vice President of Sales for Tango Networks. "With Global Pass, we empower enterprises to break free from traditional connectivity and geography constraints, fostering a new era of productivity and collaboration for the extended workforce."
Global Coverage with Borderless Roaming in 39 Countries
Global Pass liberates mobile communication from borders, enabling employees to stay connected effortlessly while traveling or working internationally.
Starting with 14 countries in the first half of 2024, Global Pass subscribers based in the USA, UK, Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Mexico, Luxembourg, Spain, Sweden, and Poland will be able to be resident or move freely between these countries and roam into 25 more countries across Europe and North America without the fear of incurring additional 'roaming' charges. Check coverage availability here: https://tango-networks.com/country-availability/
Later in 2024 and into 2025, Global Pass will expand to countries across Asia, Australasia, North and South America.
Seamless Integration for Mobile UC
Integrating with many leading UC platforms including Microsoft’s Teams Phone, Tango Extend enables workers to use their existing business numbers natively on their mobile phones, including Bring-Your-Own-Device (BYOD) mobile phones. Tango Extend provides a business e-SIM for any multi-SIM personal mobile phone. The eSIM is paid for and controlled by the business, allowing work communications and personal communications to be securely separated with dual personas. Business calls are made using the phone’s native dialer, rather than a mobile app.
Companies using Tango Extend are retiring landline desk phones, cutting expensive company-issued mobile phones, whilst at the same time reducing their carbon footprint and boosting worker productivity.
Incorporating groundbreaking fixed-mobile convergence technologies, Tango Extend is covered by more than 100 patents and has won more than 10 best new product and channel solution awards.
About Tango Networks:
Tango Networks is a pioneering force in providing cutting-edge mobile telecommunications solutions for enterprises globally. With a focus on innovation and customer-centricity, Tango Networks continues to revolutionize how businesses connect and communicate in a mobile-centric world.
Global Pass is available for immediate deployment, offering enterprises a transformative approach to mobile connectivity. For more details on Global Pass and Tango Networks' comprehensive suite of mobile telecommunications solutions, please visit tango-networks.com.
Tango Extend is a trademark of Tango Networks Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312069630/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom